Advanced search
1 file | 364.36 KB Add to list

Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer

(2020) JOURNAL FOR IMMUNOTHERAPY OF CANCER. 8(Supplement: 3). p.A207-A208
Author
Organization

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 364.36 KB

Citation

Please use this url to cite or link to this publication:

MLA
Dorff, Tanya, et al. “Phase 1 Study of AMG 160, a Half-Life Extended BITE (R) (Bispecific T-Cell Engager) Therapy Targeting Prostate-Specific Membrane Antigen, in Patients with Metastatic Castration-Resistant Prostate Cancer.” JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 8, no. Supplement: 3, Bmj Publishing Group, 2020, pp. A207–08, doi:10.1136/jitc-2020-SITC2020.0340.
APA
Dorff, T., Rettig, M., Machiels, J.-P., Lolkema, M., Autio, K., Greil, R., … Horvath, L. (2020). Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer. In JOURNAL FOR IMMUNOTHERAPY OF CANCER (Vol. 8, pp. A207–A208). Online: Bmj Publishing Group. https://doi.org/10.1136/jitc-2020-SITC2020.0340
Chicago author-date
Dorff, Tanya, Matthew Rettig, Jean-Pascal Machiels, Martijn Lolkema, Karen Autio, Richard Greil, Sylvie Rottey, et al. 2020. “Phase 1 Study of AMG 160, a Half-Life Extended BITE (R) (Bispecific T-Cell Engager) Therapy Targeting Prostate-Specific Membrane Antigen, in Patients with Metastatic Castration-Resistant Prostate Cancer.” In JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8:A207–8. Bmj Publishing Group. https://doi.org/10.1136/jitc-2020-SITC2020.0340.
Chicago author-date (all authors)
Dorff, Tanya, Matthew Rettig, Jean-Pascal Machiels, Martijn Lolkema, Karen Autio, Richard Greil, Sylvie Rottey, Nabil Adra, Mark Salvati, Shirley Poon, Daniel Tan, Gabor Jurida, Hosein Kouros-Mehr, Karim Fizazi, Ben Tran, and Lisa Horvath. 2020. “Phase 1 Study of AMG 160, a Half-Life Extended BITE (R) (Bispecific T-Cell Engager) Therapy Targeting Prostate-Specific Membrane Antigen, in Patients with Metastatic Castration-Resistant Prostate Cancer.” In JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8:A207–A208. Bmj Publishing Group. doi:10.1136/jitc-2020-SITC2020.0340.
Vancouver
1.
Dorff T, Rettig M, Machiels J-P, Lolkema M, Autio K, Greil R, et al. Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer. In: JOURNAL FOR IMMUNOTHERAPY OF CANCER. Bmj Publishing Group; 2020. p. A207–8.
IEEE
[1]
T. Dorff et al., “Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer,” in JOURNAL FOR IMMUNOTHERAPY OF CANCER, Online, 2020, vol. 8, no. Supplement: 3, pp. A207–A208.
@inproceedings{8697600,
  articleno    = {{340}},
  author       = {{Dorff, Tanya and Rettig, Matthew and Machiels, Jean-Pascal and Lolkema, Martijn and Autio, Karen and Greil, Richard and Rottey, Sylvie and Adra, Nabil and Salvati, Mark and Poon, Shirley and Tan, Daniel and Jurida, Gabor and Kouros-Mehr, Hosein and Fizazi, Karim and Tran, Ben and Horvath, Lisa}},
  booktitle    = {{JOURNAL FOR IMMUNOTHERAPY OF CANCER}},
  issn         = {{2051-1426}},
  language     = {{eng}},
  location     = {{Online}},
  number       = {{Supplement: 3}},
  pages        = {{340:A207--340:A208}},
  publisher    = {{Bmj Publishing Group}},
  title        = {{Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer}},
  url          = {{http://dx.doi.org/10.1136/jitc-2020-SITC2020.0340}},
  volume       = {{8}},
  year         = {{2020}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: